Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) FCF Margin (2021 - 2025)

Historic FCF Margin for Allogene Therapeutics (ALLO) over the last 4 years, with Q1 2024 value amounting to 254122.73%.

  • Allogene Therapeutics' FCF Margin fell 285427300.0% to 254122.73% in Q1 2024 from the same period last year, while for Dec 2024 it was 913609.09%, marking a year-over-year decrease of 6617680400.0%. This contributed to the annual value of 913609.09% for FY2024, which is 6617680400.0% down from last year.
  • According to the latest figures from Q1 2024, Allogene Therapeutics' FCF Margin is 254122.73%, which was down 285427300.0% from 256609.52% recorded in Q4 2023.
  • Allogene Therapeutics' FCF Margin's 5-year high stood at 61.03% during Q4 2021, with a 5-year trough of 282477.27% in Q2 2023.
  • In the last 4 years, Allogene Therapeutics' FCF Margin had a median value of 179843.59% in 2022 and averaged 166409.53%.
  • Over the last 5 years, Allogene Therapeutics' FCF Margin had its largest YoY gain of 455666200bps in 2022, and its largest YoY loss of 2000000000bps in 2022.
  • Over the past 4 years, Allogene Therapeutics' FCF Margin (Quarter) stood at 61.03% in 2021, then tumbled by -401877bps to 245338.46% in 2022, then decreased by -5bps to 256609.52% in 2023, then grew by 1bps to 254122.73% in 2024.
  • Its last three reported values are 254122.73% in Q1 2024, 256609.52% for Q4 2023, and 252463.64% during Q3 2023.